SNPHY Quote, Financials, Valuation and Earnings

Healios KK has a net margin of 14.22% compared to Santen Pharmaceutical's net margin of -107.23%. Santen Pharmaceutical's return on equity of 8.95% beat Healios KK's return on equity of -137.21%.

Santen Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Santen Pharmaceutical has higher upside potential than Healios KK, analysts believe Santen Pharmaceutical is more attractive than Healios KK.

Santen Pharmaceutical has a beta of 0.316, which suggesting that the stock is 68.4% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Santen Pharmaceutical has a quarterly dividend of $0.11 per share corresponding to a yield of 2.15%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Santen Pharmaceutical pays 44.6% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Santen Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Santen Pharmaceutical quarterly revenues are $479.6M, which are larger than Healios KK quarterly revenues of $3.2M. Santen Pharmaceutical's net income of $68.2M is higher than Healios KK's net income of -$3.4M. Notably, Santen Pharmaceutical's price-to-earnings ratio is 21.81x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Santen Pharmaceutical is 1.80x versus 22.75x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of 14.22% compared to Santen Pharmaceutical's net margin of -5.57%. Santen Pharmaceutical's return on equity of 8.95% beat PeptiDream's return on equity of 34.66%.

Santen Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Santen Pharmaceutical has higher upside potential than PeptiDream, analysts believe Santen Pharmaceutical is more attractive than PeptiDream.

Santen Pharmaceutical has a beta of 0.316, which suggesting that the stock is 68.4% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.804, suggesting its less volatile than the S&P 500 by 19.554%.

Santen Pharmaceutical has a quarterly dividend of $0.11 per share corresponding to a yield of 2.15%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Santen Pharmaceutical pays 44.6% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Santen Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Santen Pharmaceutical quarterly revenues are $479.6M, which are larger than PeptiDream quarterly revenues of $36.8M. Santen Pharmaceutical's net income of $68.2M is higher than PeptiDream's net income of -$2.1M. Notably, Santen Pharmaceutical's price-to-earnings ratio is 21.81x while PeptiDream's PE ratio is 21.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Santen Pharmaceutical is 1.80x versus 7.43x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 14.22% compared to Santen Pharmaceutical's net margin of 12.96%. Santen Pharmaceutical's return on equity of 8.95% beat Nxera Pharma's return on equity of -5.58%.

Santen Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Santen Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Santen Pharmaceutical is more attractive than Nxera Pharma.

Santen Pharmaceutical has a beta of 0.316, which suggesting that the stock is 68.4% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.86%.

Santen Pharmaceutical has a quarterly dividend of $0.11 per share corresponding to a yield of 2.15%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Santen Pharmaceutical pays 44.6% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Santen Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Santen Pharmaceutical quarterly revenues are $479.6M, which are larger than Nxera Pharma quarterly revenues of $62.4M. Santen Pharmaceutical's net income of $68.2M is higher than Nxera Pharma's net income of $8.1M. Notably, Santen Pharmaceutical's price-to-earnings ratio is 21.81x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Santen Pharmaceutical is 1.80x versus 2.95x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 14.22% compared to Santen Pharmaceutical's net margin of 7.83%. Santen Pharmaceutical's return on equity of 8.95% beat Takeda Pharmaceutical's return on equity of 4.01%.

Santen Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $15.73 which suggests that it could grow by 19.62%. Given that Takeda Pharmaceutical has higher upside potential than Santen Pharmaceutical, analysts believe Takeda Pharmaceutical is more attractive than Santen Pharmaceutical.

Santen Pharmaceutical has a beta of 0.316, which suggesting that the stock is 68.4% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.642%.

Santen Pharmaceutical has a quarterly dividend of $0.11 per share corresponding to a yield of 2.15%. Takeda Pharmaceutical offers a yield of 4.65% to investors and pays a quarterly dividend of $0.33 per share. Santen Pharmaceutical pays 44.6% of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend. Santen Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

Santen Pharmaceutical quarterly revenues are $479.6M, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.9B. Santen Pharmaceutical's net income of $68.2M is lower than Takeda Pharmaceutical's net income of $619.7M. Notably, Santen Pharmaceutical's price-to-earnings ratio is 21.81x while Takeda Pharmaceutical's PE ratio is 22.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Santen Pharmaceutical is 1.80x versus 1.40x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.